Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.48 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560551 | 0.96 | KEAP1 (0.54) | KEAP1NFE2L2SLC16A3MEN1KMT2A | |
| SCHEMBL3557703 | 0.95 | KEAP1 (0.53) | KEAP1NFE2L2SLC16A3MEN1KMT2A | |
| SCHEMBL3559360 | 0.87 | LMNA (0.61) | KEAP1NFE2L2SLC16A3MEN1KMT2A | |
| SCHEMBL3561994 | 0.87 | SLC16A3 (0.73) | KEAP1NFE2L2SLC16A3AKR1C3 | |
| SCHEMBL23200342 | 0.87 | MEN1 (0.66) | KEAP1NFE2L2SLC16A3MEN1KMT2A | |
| SCHEMBL3555833 | 0.86 | PGR (0.60) | MEN1KMT2APGRAKR1C3 | |
| SCHEMBL3561861 | 0.86 | SLC16A3 (0.70) | KEAP1NFE2L2SLC16A3AKR1C3 | |
| SCHEMBL3563734 | 0.85 | AKR1C3 (0.53) | KEAP1NFE2L2SLC16A3MEN1KMT2A | |
| SCHEMBL3554601 | 0.85 | MEN1 (0.57) | SLC16A3MEN1KMT2AGAA | |
| SCHEMBL3561138 | 0.84 | SMN1; SMN2 (0.59) | KEAP1NFE2L2SLC16A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | KEAP1 1284/4885NFE2L2 896/4885SLC16A3 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.